Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis

B. Lyons-Giordano, C. S. Chen, Gerald Sylvan Lazarus, P. J. Jensen, D. Loskutoff, M. Keeton

Research output: Contribution to journalArticle

Abstract

The plasminogen activator (PA) proteolytic cascade has been implicated in the regulation of cell activities, including proliferation and differentiation, both of which occur continuously in normal human epidermis and are aberrant in psoriatic epidermis. To elucidate further the mechanisms by which PA is regulated in epidermis, we evaluated the levels of PA inhibitors type 1 (PAI-1) and type 2 (PAI-2) in normal and psoriatic epidermis. PAI-2, but not PAI-1, was detectable by mRNA, antigen, and activity assays, indicating that PAI-2 is the predominant epidermal PA inhibitor. In situ hybridization revealed that PAI-2 mRNA occurred throughout normal epidermis, although the signal was most intense in the granular layers. Similarly, PAI-2 antigen was most prominent in the granular layers; its distribution in these differential layers was along the cell periphery. Diffuse, fainter staining for PAI-2 was also detected in the basal cells and in some spinous layers of normal epidermis. Extracts of normal epidermis contained PA inhibitory activity identified as PAI-2 by immunoprecipitation with specific antibody. In psoriatic epidermis, PAI-2 mRNA and antigen were most prominent in the more superficial layers beneath the cornified cells. As with normal epidermis, PAI-2 assumed a pericellular distribution in the psoriatic cells. These data demonstrate that PAI-2 is constitutively expressed in vivo by keratinocytes in human epidermis and indicate that this protein is the predominant inhibitor of PA activity in normal and psoriatic human epidermis.

Original languageEnglish (US)
Pages (from-to)105-112
Number of pages8
JournalHistochemistry
Volume101
Issue number2
DOIs
StatePublished - Feb 1994
Externally publishedYes

Fingerprint

Plasminogen Activator Inhibitor 2
epidermis (animal)
Epidermis
Plasminogen Activator Inhibitor 1
plasminogen activator
Plasminogen Activators
Plasminogen Inactivators
antigens
Antigens
Messenger RNA
cells
plasminogen activator inhibitors
keratinocytes
Keratinocytes
Immunoprecipitation
in situ hybridization
In Situ Hybridization

ASJC Scopus subject areas

  • Anatomy

Cite this

Lyons-Giordano, B., Chen, C. S., Lazarus, G. S., Jensen, P. J., Loskutoff, D., & Keeton, M. (1994). Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochemistry, 101(2), 105-112. https://doi.org/10.1007/BF00269356

Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. / Lyons-Giordano, B.; Chen, C. S.; Lazarus, Gerald Sylvan; Jensen, P. J.; Loskutoff, D.; Keeton, M.

In: Histochemistry, Vol. 101, No. 2, 02.1994, p. 105-112.

Research output: Contribution to journalArticle

Lyons-Giordano, B, Chen, CS, Lazarus, GS, Jensen, PJ, Loskutoff, D & Keeton, M 1994, 'Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis', Histochemistry, vol. 101, no. 2, pp. 105-112. https://doi.org/10.1007/BF00269356
Lyons-Giordano, B. ; Chen, C. S. ; Lazarus, Gerald Sylvan ; Jensen, P. J. ; Loskutoff, D. ; Keeton, M. / Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. In: Histochemistry. 1994 ; Vol. 101, No. 2. pp. 105-112.
@article{dc1d32f4083747f8ac4347534dbe5e4b,
title = "Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis",
abstract = "The plasminogen activator (PA) proteolytic cascade has been implicated in the regulation of cell activities, including proliferation and differentiation, both of which occur continuously in normal human epidermis and are aberrant in psoriatic epidermis. To elucidate further the mechanisms by which PA is regulated in epidermis, we evaluated the levels of PA inhibitors type 1 (PAI-1) and type 2 (PAI-2) in normal and psoriatic epidermis. PAI-2, but not PAI-1, was detectable by mRNA, antigen, and activity assays, indicating that PAI-2 is the predominant epidermal PA inhibitor. In situ hybridization revealed that PAI-2 mRNA occurred throughout normal epidermis, although the signal was most intense in the granular layers. Similarly, PAI-2 antigen was most prominent in the granular layers; its distribution in these differential layers was along the cell periphery. Diffuse, fainter staining for PAI-2 was also detected in the basal cells and in some spinous layers of normal epidermis. Extracts of normal epidermis contained PA inhibitory activity identified as PAI-2 by immunoprecipitation with specific antibody. In psoriatic epidermis, PAI-2 mRNA and antigen were most prominent in the more superficial layers beneath the cornified cells. As with normal epidermis, PAI-2 assumed a pericellular distribution in the psoriatic cells. These data demonstrate that PAI-2 is constitutively expressed in vivo by keratinocytes in human epidermis and indicate that this protein is the predominant inhibitor of PA activity in normal and psoriatic human epidermis.",
author = "B. Lyons-Giordano and Chen, {C. S.} and Lazarus, {Gerald Sylvan} and Jensen, {P. J.} and D. Loskutoff and M. Keeton",
year = "1994",
month = "2",
doi = "10.1007/BF00269356",
language = "English (US)",
volume = "101",
pages = "105--112",
journal = "Histochemistry and Cell Biology",
issn = "0948-6143",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis

AU - Lyons-Giordano, B.

AU - Chen, C. S.

AU - Lazarus, Gerald Sylvan

AU - Jensen, P. J.

AU - Loskutoff, D.

AU - Keeton, M.

PY - 1994/2

Y1 - 1994/2

N2 - The plasminogen activator (PA) proteolytic cascade has been implicated in the regulation of cell activities, including proliferation and differentiation, both of which occur continuously in normal human epidermis and are aberrant in psoriatic epidermis. To elucidate further the mechanisms by which PA is regulated in epidermis, we evaluated the levels of PA inhibitors type 1 (PAI-1) and type 2 (PAI-2) in normal and psoriatic epidermis. PAI-2, but not PAI-1, was detectable by mRNA, antigen, and activity assays, indicating that PAI-2 is the predominant epidermal PA inhibitor. In situ hybridization revealed that PAI-2 mRNA occurred throughout normal epidermis, although the signal was most intense in the granular layers. Similarly, PAI-2 antigen was most prominent in the granular layers; its distribution in these differential layers was along the cell periphery. Diffuse, fainter staining for PAI-2 was also detected in the basal cells and in some spinous layers of normal epidermis. Extracts of normal epidermis contained PA inhibitory activity identified as PAI-2 by immunoprecipitation with specific antibody. In psoriatic epidermis, PAI-2 mRNA and antigen were most prominent in the more superficial layers beneath the cornified cells. As with normal epidermis, PAI-2 assumed a pericellular distribution in the psoriatic cells. These data demonstrate that PAI-2 is constitutively expressed in vivo by keratinocytes in human epidermis and indicate that this protein is the predominant inhibitor of PA activity in normal and psoriatic human epidermis.

AB - The plasminogen activator (PA) proteolytic cascade has been implicated in the regulation of cell activities, including proliferation and differentiation, both of which occur continuously in normal human epidermis and are aberrant in psoriatic epidermis. To elucidate further the mechanisms by which PA is regulated in epidermis, we evaluated the levels of PA inhibitors type 1 (PAI-1) and type 2 (PAI-2) in normal and psoriatic epidermis. PAI-2, but not PAI-1, was detectable by mRNA, antigen, and activity assays, indicating that PAI-2 is the predominant epidermal PA inhibitor. In situ hybridization revealed that PAI-2 mRNA occurred throughout normal epidermis, although the signal was most intense in the granular layers. Similarly, PAI-2 antigen was most prominent in the granular layers; its distribution in these differential layers was along the cell periphery. Diffuse, fainter staining for PAI-2 was also detected in the basal cells and in some spinous layers of normal epidermis. Extracts of normal epidermis contained PA inhibitory activity identified as PAI-2 by immunoprecipitation with specific antibody. In psoriatic epidermis, PAI-2 mRNA and antigen were most prominent in the more superficial layers beneath the cornified cells. As with normal epidermis, PAI-2 assumed a pericellular distribution in the psoriatic cells. These data demonstrate that PAI-2 is constitutively expressed in vivo by keratinocytes in human epidermis and indicate that this protein is the predominant inhibitor of PA activity in normal and psoriatic human epidermis.

UR - http://www.scopus.com/inward/record.url?scp=0028333830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028333830&partnerID=8YFLogxK

U2 - 10.1007/BF00269356

DO - 10.1007/BF00269356

M3 - Article

C2 - 8071082

AN - SCOPUS:0028333830

VL - 101

SP - 105

EP - 112

JO - Histochemistry and Cell Biology

JF - Histochemistry and Cell Biology

SN - 0948-6143

IS - 2

ER -